LIFEVANTAGE CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares.
- LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares.
- LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares.
- LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2026 was 0.00 shares.
- LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 0.00 shares.
- LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 0.00 shares.
- LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-27 | 0.00 shares 10-K · filed 2026-08-27 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-06 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-12-31 | 0.00 shares 10-Q · filed 2026-02-04 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-09-30 | 0.00 shares 10-Q · filed 2025-11-04 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-06-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-27 | 0.00 shares 10-K · filed 2026-08-27 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2026-05-06 | 0.00 shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | 0.00 shares 10-Q · filed 2026-02-04 | 0.00 shares derived: sum of 4 quarters · filed 2026-02-04 |
| 2024-09-30 | 0.00 shares 10-Q · filed 2025-11-04 | 0.00 shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-04 | 0.00 shares 10-K · filed 2025-09-04 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2025-05-06 | |
| 2023-12-31 | 0.00 shares 10-Q · filed 2025-02-05 | |
| 2023-09-30 | 0.00 shares 10-Q · filed 2024-10-29 | |
| 2023-06-30 | 0.00 shares 10-K · filed 2024-08-28 | |
| 2023-03-31 | 0.00 shares 10-Q · filed 2024-05-02 | |
| 2022-12-31 | 0.00 shares 10-Q · filed 2024-01-30 | |
| 2022-06-30 | 30.00K shares 10-K · filed 2023-08-28 | |
| 2021-06-30 | 289.00K shares 10-K · filed 2022-08-23 | |
| 2020-06-30 | 25.00K shares 10-K · filed 2022-08-23 | |
| 2019-06-30 | 155.00K shares 10-K · filed 2021-08-19 | |
| 2013-06-30 | 1.82M shares derived: 10-K 12 month − 10-Q 9 month · filed 2013-09-12 | 3.32M shares 10-K · filed 2013-09-12 |
| 2013-03-31 | 957.00K shares 10-Q · filed 2013-05-09 | |
| 2012-12-31 | 464.37K shares 10-Q · filed 2013-02-07 | |
| 2012-09-30 | 96.50K shares 10-Q · filed 2012-11-08 | |
| 2012-06-30 | 1.61M shares 10-K · filed 2013-09-12 | |
| 2011-06-30 | 470.00K shares 10-K · filed 2013-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |